Chase is a Research Analyst at Fisher Investments and has been with the firm since 2013.
Capping prescription drug prices would be a negative for the industry, but even if the idea became legislation, it isn’t likely to pass through the political gauntlet.
Get a weekly roundup of our market insights.Sign up for the MarketMinder email newsletter. Learn more.
If you are interested in learning more about Fisher Investments, please click here to visit our new corporate website: